Furthermore, RUXO has not been optimized for use in neurological disorders in humans, and a myriad of direct and off-target side effects on CNS have been attributed to RUXO and other JAK/STAT pathway inhibitors spanning from dizziness, peripheral neuropathy, ataxia, speech dysfunction, amnesia, to Wernicke encephalopathy [64], which may limit the usefulness of current STAT3 inhibitory molecules. This evidence concerns the gene SOAT1 and cerebellar ataxia.